<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-1404336851463042010</id><updated>2024-11-08T07:29:49.015-08:00</updated><category term="Avastin"/><category term="Breast cancer"/><category term="cancer"/><category term="Blood pressure drugs"/><category term="C. difficile"/><category term="FDA"/><category term="G2 cell cycle phase"/><category term="PPI"/><category term="Proton pump inhibitors"/><category term="Tai Chi"/><category term="angiotensin-receptor blocker"/><category term="apoptosis"/><category term="bevacizumab"/><category term="bone"/><category term="bone density"/><category term="bone mineral"/><category term="caffeine"/><category term="chemotherapy"/><category term="exercise"/><category term="fibromyalgia"/><category term="lean muscle"/><category term="malignant"/><category term="mood"/><category term="muscle"/><category term="muscle mass"/><category term="phychological health"/><category term="physical activity"/><category term="reccurence"/><category term="resistance training"/><category term="stem cells"/><category term="strength enhancement"/><category term="well-being"/><title type='text'>MedWrite Healthcare Communications</title><subtitle type='html'>We are a healthcare communication service built on a strong foundation of an extensive science background combined with a healthcare advertising agency and continuing medical education(CME) experience.</subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>21</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-5653062557635846437</id><published>2014-05-14T17:10:00.001-07:00</published><updated>2014-05-14T17:10:55.644-07:00</updated><title type='text'>Inside stomach Ramen Noodle digestion goes viral</title><content type='html'>&lt;iframe allowfullscreen=&quot;&quot; frameborder=&quot;0&quot; height=&quot;270&quot; src=&quot;//www.youtube.com/embed/IQlNv2Au-Lg&quot; width=&quot;480&quot;&gt;&lt;/iframe&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/5653062557635846437/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2014/05/inside-stomach-ramen-noodle-digestion.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/5653062557635846437'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/5653062557635846437'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2014/05/inside-stomach-ramen-noodle-digestion.html' title='Inside stomach Ramen Noodle digestion goes viral'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-1445629674089457881</id><published>2014-05-13T18:07:00.000-07:00</published><updated>2014-05-13T18:09:20.666-07:00</updated><title type='text'>The Panov Program - Precision Chemotherapy / Mt. Sinai Hospital Toronto,...</title><content type='html'>&lt;iframe allowfullscreen=&quot;&quot; frameborder=&quot;0&quot; height=&quot;270&quot; src=&quot;//www.youtube.com/embed/Nt1w0hBjsZs&quot; width=&quot;480&quot;&gt;&lt;/iframe&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/1445629674089457881/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2014/05/the-panov-program-precision.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/1445629674089457881'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/1445629674089457881'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2014/05/the-panov-program-precision.html' title='The Panov Program - Precision Chemotherapy / Mt. Sinai Hospital Toronto,...'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-8583722125339093255</id><published>2013-09-07T12:25:00.003-07:00</published><updated>2013-09-07T12:25:54.839-07:00</updated><title type='text'>Mini-review of THE PLAN by Lyn-Genet Recitas</title><content type='html'>&lt;div class=&quot;ecxMsoNormal&quot; style=&quot;background-color: white; color: #444444; font-family: Calibri, sans-serif; font-size: 11pt; line-height: 20px; margin-bottom: 1.35em;&quot;&gt;
&lt;span style=&quot;color: #943634; font-family: &#39;Comic Sans MS&#39;; font-size: 12pt; line-height: 22.727272033691406px;&quot;&gt;I just bought the book,&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;color: #943634; font-family: &#39;Comic Sans MS&#39;; font-size: 16.363636016845703px; line-height: 22.727272033691406px;&quot;&gt;THE PLAN by Lyn-Genet Recitas,&lt;/span&gt;&lt;span style=&quot;color: #943634; font-family: &#39;Comic Sans MS&#39;; font-size: 16.363636016845703px; line-height: 22.727272033691406px;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;color: #943634; font-family: &#39;Comic Sans MS&#39;; font-size: 12pt; line-height: 22.727272033691406px;&quot;&gt;after hearing about it on either Dr Oz or some other health-related show.&amp;nbsp;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;ecxMsoNormal&quot; style=&quot;background-color: white; color: #444444; font-family: Calibri, sans-serif; font-size: 11pt; line-height: 20px; margin-bottom: 1.35em;&quot;&gt;
&lt;span style=&quot;color: #943634; font-family: &#39;Comic Sans MS&#39;; font-size: 12pt; line-height: 22.727272033691406px;&quot;&gt;The book’s main claim is “Eliminate the surprising “healthy” foods that are making you fat –- and lose weight fast”. While I don’t fall for claims that promise fast weight loss, I was intrigued by the idea of so-called “healthy” foods that contribute to weight gain since my diet consists of “healthy” foods and I struggle to keep my weight down.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;ecxMsoNormal&quot; style=&quot;background-color: white; margin-bottom: 1.35em;&quot;&gt;
&lt;span style=&quot;color: #943634; font-family: &#39;Comic Sans MS&#39;; font-size: 12pt; line-height: 22.727272033691406px;&quot;&gt;So I started reading THE PLAN...It is full of case studies of people (fictional or real...hard to tell), and not a single reference to any study that would support any of the claims made throughout the book (to me it’s always a red flag)! While&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;color: #943634; font-family: &#39;Comic Sans MS&#39;; font-size: 12pt; line-height: 22.727272033691406px;&quot;&gt;Recitas is convincing in her tone, and her unsupported claims almost make sense, but lack of references, for me, puts this book into FICTION category.&lt;/span&gt;&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/8583722125339093255/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/09/mini-review-of-plan-by-lyn-genet-recitas.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8583722125339093255'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8583722125339093255'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/09/mini-review-of-plan-by-lyn-genet-recitas.html' title='Mini-review of THE PLAN by Lyn-Genet Recitas'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-7700779202280070364</id><published>2013-06-29T15:26:00.001-07:00</published><updated>2013-06-29T15:26:06.224-07:00</updated><title type='text'>Eat To Live | Fast and Sustained Weight Loss | Healthy, Nutritous Diet that Prevents and Reverses Disease | DrFuhrman.com</title><content type='html'>&lt;a href=&quot;http://www.drfuhrman.com/shop/ETLBook.aspx#.Uc9euALo4XI.blogger&quot;&gt;Eat To Live | Fast and Sustained Weight Loss | Healthy, Nutritous Diet that Prevents and Reverses Disease | DrFuhrman.com&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/7700779202280070364/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/06/eat-to-live-fast-and-sustained-weight.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/7700779202280070364'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/7700779202280070364'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/06/eat-to-live-fast-and-sustained-weight.html' title='Eat To Live | Fast and Sustained Weight Loss | Healthy, Nutritous Diet that Prevents and Reverses Disease | DrFuhrman.com'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-4954075009759846833</id><published>2013-06-03T11:38:00.001-07:00</published><updated>2013-06-03T11:42:17.361-07:00</updated><title type='text'>Canagliflozin: “new class” of diabetes drug approved in the U.S., and under review  in Canada</title><content type='html'>&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;Canagliflozin -- the once-a-day oral pill &amp;nbsp;-- belongs to a “new class” of diabetes medication&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;has been approved by the U.S.&amp;nbsp;Food and Drug Administration (FDA) on March 29, 2013. The drug&#39;s mode of action is in the kidneys to inhibit sodium-glucose cotransporter 2 (SGLT2).&amp;nbsp;&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
&quot;&lt;i&gt;After glucose is filtered from the blood into the kidneys, canagliflozin suppresses SGLT2 t&lt;/i&gt;&lt;i&gt;ransporters from carrying the glucose back into the blood. Instead, the glucose is&amp;nbsp;&lt;/i&gt;&lt;i&gt;diverted and released into the urine. This effectively pushes excess blood glucose out of&amp;nbsp;&lt;/i&gt;&lt;i&gt;the body via the kidneys and urinary tract.&lt;/i&gt;&quot;&lt;br /&gt;
&lt;br /&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;Canagliflozin is currently pending approval by Health Canada.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;&lt;br /&gt;&lt;/span&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;To download full-text article, &lt;a href=&quot;http://www.cmaj.ca/content/early/2013/06/03/cmaj.109-4483&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: blue;&quot;&gt;Click Here&lt;/span&gt;&lt;/a&gt;.&amp;nbsp;&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;u&gt;&lt;br /&gt;&lt;/u&gt;
&lt;u&gt;Source:&lt;/u&gt; Published in the Canadian Medical Association Journal (www.cmaj.ca). June 3, 2013.</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/4954075009759846833/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/06/canagliflozin-new-class-of-diabetes.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/4954075009759846833'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/4954075009759846833'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/06/canagliflozin-new-class-of-diabetes.html' title='Canagliflozin: “new class” of diabetes drug approved in the U.S., and under review  in Canada'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-1993509045216125538</id><published>2013-06-03T11:03:00.001-07:00</published><updated>2013-06-03T11:41:43.825-07:00</updated><title type='text'>In the UK, doctors will have to show fitness to practise every five years</title><content type='html'>&lt;br /&gt;
&quot;&lt;i&gt;Doctors with a licence to practise in the United Kingdom from the General Medical&amp;nbsp;&lt;/i&gt;&lt;i&gt;Council (GMC) are now legally required to undergo revalidation, that is, to provide&amp;nbsp;&lt;/i&gt;&lt;i&gt;evidence of ongoing fitness to practise every five years.&lt;/i&gt;&quot; &lt;br /&gt;
&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;&lt;br /&gt;&lt;/span&gt;
T&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;o download full-text article &lt;/span&gt;&lt;a href=&quot;http://www.cmaj.ca/content/early/2013/06/03/cmaj.109-4461&quot; style=&quot;font-family: Arial, Helvetica, sans-serif;&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: blue;&quot;&gt;Click Here&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;font-family: Arial, Helvetica, sans-serif;&quot;&gt;.&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;span style=&quot;font-family: Verdana, sans-serif; font-size: x-small;&quot;&gt;&lt;br /&gt;&lt;/span&gt;
&lt;span style=&quot;font-family: Verdana, sans-serif; font-size: x-small;&quot;&gt;&lt;br /&gt;&lt;/span&gt;
&lt;span style=&quot;font-family: Verdana, sans-serif; font-size: x-small;&quot;&gt;Source: Published by the Canadian Medical Association Journal (www.cmaj.ca), May 31, 2013.&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/1993509045216125538/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/06/in-uk-doctors-will-have-to-show-fitness.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/1993509045216125538'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/1993509045216125538'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/06/in-uk-doctors-will-have-to-show-fitness.html' title='In the UK, doctors will have to show fitness to practise every five years'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-8525118959062207794</id><published>2013-06-03T09:45:00.001-07:00</published><updated>2013-06-03T09:45:29.365-07:00</updated><title type='text'>Acupuncture: Effective or placebo?</title><content type='html'>&lt;h3 class=&quot;groups title&quot; style=&quot;border: 0px; color: #333333; font-family: Arial, sans-serif; font-size: 16px; font-weight: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;br /&gt;&lt;/h3&gt;
&lt;div class=&quot;summary&quot; style=&quot;border: 0px; font-family: Arial, sans-serif; font-size: 13px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
David Colquhoun PhD and Steven Novella MD, wrote an article which concludes that acupuncture is worthless for pain relief. [Colquhoun D, Novella S. Acupuncture is theatrical placebo. Anesthesia &amp;amp; Analgesia 116:1360-1363, 2013]&amp;nbsp;&lt;span style=&quot;font-size: 13px;&quot;&gt;Their report concludes that &quot;the benefits of acupuncture are likely nonexistent, or at best are too small and too transient to be of any clinical significance.&quot; &lt;a href=&quot;http://www.anesthesia-analgesia.org/content/116/6/1360.full.pdf+html.?goback=%2Egmp_5002829%2Egde_5002829_member_246117402&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: blue;&quot;&gt;Click here&lt;/span&gt;&lt;/a&gt; for the ink to the article.&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;summary&quot; style=&quot;border: 0px; font-family: Arial, sans-serif; font-size: 13px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;summary&quot; style=&quot;border: 0px; font-family: Arial, sans-serif; font-size: 13px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
For more information, Colquhoun&#39;s blog (&lt;a href=&quot;http://www.linkedin.com/redirect?url=http%3A%2F%2Fwww%2Edcscience%2Enet%2F%3Fp%3D6060&amp;amp;urlhash=sv5G&amp;amp;_t=tracking_anet&quot; rel=&quot;nofollow&quot; style=&quot;border: 0px; color: #006699; font-family: inherit; font-style: inherit; margin: 0px; outline: 0px; padding: 0px; text-decoration: none; vertical-align: baseline;&quot; target=&quot;blank&quot;&gt;http://www.dcscience.net/?p=6060&lt;/a&gt;) contains links to supportive documents.&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;summary&quot; style=&quot;border: 0px; font-family: Arial, sans-serif; font-size: 13px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;summary&quot; style=&quot;border: 0px; font-family: Arial, sans-serif; font-size: 13px; outline: 0px; padding: 0px; vertical-align: baseline;&quot;&gt;
[Source: Consumer Health Digest Digest #13-21, May 30, 2013, edited by Stephen Barrett MD]&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/8525118959062207794/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/06/acupuncture-effective-or-placebo.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8525118959062207794'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8525118959062207794'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/06/acupuncture-effective-or-placebo.html' title='Acupuncture: Effective or placebo?'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-3647680437060976026</id><published>2013-02-12T09:41:00.001-08:00</published><updated>2013-02-12T09:41:15.277-08:00</updated><title type='text'>Living without Hope - Not an Option</title><content type='html'>&lt;div class=&quot;separator&quot; style=&quot;clear: both; text-align: right;&quot;&gt;
&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiodn1_ylyuvc41NxSiCLrbOrYRB4W7T37Ll3f-UgjqXwknH-Clvt7Xb02vWfjWG6KTvbfZc1oumMMSLIc5itK2Y1Scr_KF1AjXrXSXoFm4zZg4QbLFn3zxcYhyx3KgNWe5_5FA0OVL-wAj/s1600/Andrew+Avetikov+%2528just+photo%2529.jpg&quot; imageanchor=&quot;1&quot; style=&quot;clear: left; float: left; margin-bottom: 1em; margin-right: 1em;&quot;&gt;&lt;img alt=&quot;&quot; border=&quot;0&quot; height=&quot;161&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiodn1_ylyuvc41NxSiCLrbOrYRB4W7T37Ll3f-UgjqXwknH-Clvt7Xb02vWfjWG6KTvbfZc1oumMMSLIc5itK2Y1Scr_KF1AjXrXSXoFm4zZg4QbLFn3zxcYhyx3KgNWe5_5FA0OVL-wAj/s200/Andrew+Avetikov+%2528just+photo%2529.jpg&quot; title=&quot;&quot; width=&quot;200&quot; /&gt;&lt;/a&gt;&lt;span style=&quot;font-family: Calibri;&quot;&gt;&lt;em&gt;by Flora Krasnoshtein&lt;/em&gt;&lt;/span&gt;&lt;/div&gt;
&lt;span style=&quot;font-family: Calibri;&quot;&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&amp;nbsp;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
It was unthinkable and devastating when in 2009 at a young
age of 23, Andrew was diagnosed with cancer, and all his life’s plans come to
an abrupt halt. No longer able to think about university, career, social life,
travelling, and other things 23-year olds think about, Andrew’s focus shifted
from planning his life to fighting for his life, and he became a patient at the
Princess Margaret Hospital in Toronto, Ontario, Canada.&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-family: Times New Roman;&quot;&gt;

&lt;/span&gt;After 2 successful surgeries, Andrew was in remission for
2.5 years. But this joy did not last, because in May 2012, at the age of 26,
Andrew’s cancer returned. The worst part was that this new cancer was different
from the first one – it was rare, more aggressive and difficult to treat. This
cancer is called primitive neuroectodermal tumour or PNET for short, which affects
only about 3 to 6% of people. &lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-family: Times New Roman;&quot;&gt;

&lt;/span&gt;Andrew started chemo, and was treated from May–July 2012,
but unfortunately, the treatment did not shrink his cancer enough to operate. Doctors
decided to try another chemo, hoping that stronger drugs will be able to kill
the cancer. After being on the new chemo from October 2012–January 2013, doctors
decided to stop the treatment because this chemo did not work either. Andrew is
now receiving another chemo treatment, and is hopeful that this time the
tumours will shrink. This toxic and emotional rollercoaster ride has not weakened
Andrew’s resolve. He is hopeful that this time the chemo will work in
eradicating his tumours, and he can once again resume his life where it came to
an abrupt halt when he was 23. For Andrew, living without hope is simply not an
option!&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-family: Times New Roman;&quot;&gt;

&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;strong&gt;Ways to Donate to Andrew’s Health Fund:&lt;/strong&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-family: Times New Roman;&quot;&gt;

&lt;/span&gt;You can make a contribution at &lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;any&lt;/b&gt; &lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;CIBC branch&lt;/b&gt; in
either Canadian or US funds to Andrew’s Trust Account.&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
To donate in &lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;Canadian&lt;/b&gt;
funds, please make cheques payable to: &lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;00122/59
– 12091 &lt;/b&gt;(&lt;u&gt;&lt;span style=&quot;mso-bidi-font-family: Arial; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;&quot;&gt;Andrew Avetikov)&lt;/span&gt;&lt;/u&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
To donate in &lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;US&lt;/b&gt;
funds, please make cheques payable to: &lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;00122/94
– 72037 &lt;/b&gt;(&lt;u&gt;&lt;span style=&quot;mso-bidi-font-family: Arial; mso-fareast-font-family: &amp;quot;Times New Roman&amp;quot;;&quot;&gt;Andrew Avetikov)&lt;/span&gt;&lt;/u&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-family: Times New Roman;&quot;&gt;

&lt;/span&gt;&lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;The cheques can be
sent to:&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp; &lt;/span&gt;&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/b&gt;CIBC Investor Services Inc. 302 ─ 7501 Keele Street. Concord ON, CANADA &lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;L4K 1Y2&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-family: Times New Roman;&quot;&gt;

&lt;/span&gt;To make a contribution via &lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;PayPal&lt;/b&gt;, please visit &lt;a href=&quot;http://www.oncleanicepro.com/andrew/andrew.html&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: blue;&quot;&gt;Help Support Andrew Avetikov Health Fund website&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt; and click on &lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;Donate &lt;/b&gt;button.&lt;b style=&quot;mso-bidi-font-weight: normal;&quot;&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/b&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-family: Times New Roman;&quot;&gt;

&lt;/span&gt;Please visit Andrew Avetikov’s Health Fund page on &lt;a href=&quot;https://www.facebook.com/pages/Andrew-Avetikovs-Health-Fund/487664297941785&quot; target=&quot;_blank&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: blue;&quot;&gt;Facebook&lt;/span&gt;&lt;/strong&gt;&lt;/a&gt;&lt;span style=&quot;color: blue;&quot;&gt; &lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt; text-align: center;&quot;&gt;
&lt;span style=&quot;font-family: Times New Roman;&quot;&gt;

&lt;/span&gt;&lt;span style=&quot;font-size: 9pt; line-height: 115%;&quot;&gt;All unused
funds will be donated to the Princess Margaret Hospital in Toronto and the
Canadian Cancer Society.&lt;/span&gt;&lt;/div&gt;
&lt;/span&gt;&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt; text-align: center;&quot;&gt;
&lt;span style=&quot;font-family: Calibri;&quot;&gt;&lt;strong&gt;_________________________________&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-family: Calibri;&quot;&gt;&lt;strong&gt;Andrew Avetikov is a 26-year old, living in Thornhill,
Ontario, Canada. An avid basketball fan, Andrew does not miss an opportunity to
cheer for his favourite basketball team, The Toronto Raptors, and his favourite
player, Lebron James! A wiz with electronic devices, Andrew is always ahead of
the game in the world of technology. Born in Toronto, Canada in 1986, Andrew attended
Montessori School, Kumon, Toronto French School, University of Western Ontario
and York University. Hobbies abound, Andrew is an accomplished swimmer and
skater, played hockey and tennis, and even figure skated. Andrew is fluent in
multiple languages including English, French, and Russian. Always surrounded by
friends, Andrew is popular and loved by everyone. Sidelined by cancer from the
age of 23, Andrew’s life now revolves around cancer treatments, chemo
appointments, CT scans, and blood tests.&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;
&lt;/span&gt;Andrew is battling a rare, treatment-resistant form of cancer called
primitive neuroectodermal tumour (PNET), and is currently on his third chemo
regimen at the Princess Margaret Hospital in Toronto.&lt;/strong&gt;&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-family: &amp;quot;Verdana&amp;quot;,&amp;quot;sans-serif&amp;quot;; font-size: 12pt; line-height: 115%;&quot;&gt;&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/span&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&amp;nbsp;&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/3647680437060976026/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/02/living-without-hope-not-option_12.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/3647680437060976026'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/3647680437060976026'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/02/living-without-hope-not-option_12.html' title='Living without Hope - Not an Option'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiodn1_ylyuvc41NxSiCLrbOrYRB4W7T37Ll3f-UgjqXwknH-Clvt7Xb02vWfjWG6KTvbfZc1oumMMSLIc5itK2Y1Scr_KF1AjXrXSXoFm4zZg4QbLFn3zxcYhyx3KgNWe5_5FA0OVL-wAj/s72-c/Andrew+Avetikov+%2528just+photo%2529.jpg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-5864857356049547287</id><published>2013-02-01T06:25:00.000-08:00</published><updated>2013-02-01T06:26:41.832-08:00</updated><title type='text'>Help Support Andrew&#39;s Health Fund</title><content type='html'>&lt;div class=&quot;separator&quot; style=&quot;clear: both; text-align: center;&quot;&gt;
&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhF1TbDXrs5AkrJWY99K-ED5JhFAC25k3qdwqqGSJsGhe-kVOqec3uMtQfegV-h2S4gfZ67wl2digJ8sAGQhSFiZuAJkv-mKgKiwbNsSjryusS1lPah4ZzsIAoFEDjMrE4oM0ymGxF50Ffo/s1600/Andrew+Avetikov.jpg&quot; imageanchor=&quot;1&quot; style=&quot;margin-left: 1em; margin-right: 1em;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;106&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhF1TbDXrs5AkrJWY99K-ED5JhFAC25k3qdwqqGSJsGhe-kVOqec3uMtQfegV-h2S4gfZ67wl2digJ8sAGQhSFiZuAJkv-mKgKiwbNsSjryusS1lPah4ZzsIAoFEDjMrE4oM0ymGxF50Ffo/s320/Andrew+Avetikov.jpg&quot; width=&quot;320&quot; /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;div class=&quot;separator&quot; style=&quot;clear: both; text-align: center;&quot;&gt;
&amp;nbsp;&lt;/div&gt;
&lt;div class=&quot;separator&quot; style=&quot;clear: both; text-align: center;&quot;&gt;
&amp;nbsp;&lt;/div&gt;
&lt;span style=&quot;font-size: 12pt; line-height: 115%;&quot;&gt;&lt;span style=&quot;font-family: Calibri;&quot;&gt;&lt;span style=&quot;color: red;&quot;&gt;&lt;strong&gt;CANCER.&lt;/strong&gt;&lt;/span&gt; It touches
all our lives ― either directly or indirectly. My cousin Andrew is battling
cancer, and we need help to raise funds for his cancer treatments not available
in Canada. Please read and share his story. &lt;span style=&quot;color: black;&quot;&gt;While
there is no expectation for you to donate, if you are able to give any amount
you feel appropriate to Andrew’s Health Fund, we will greatly appreciate it.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-size: 12pt; line-height: 115%;&quot;&gt;&lt;span style=&quot;font-family: Calibri;&quot;&gt;Web Page&lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;a href=&quot;http://www.oncleanicepro.com/andrew/andrew.html&quot;&gt;&lt;span style=&quot;color: blue; font-family: Calibri;&quot;&gt;http://www.oncleanicepro.com/andrew/andrew.html&lt;/span&gt;&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/div&gt;
&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot; style=&quot;margin: 0cm 0cm 10pt;&quot;&gt;
&lt;span style=&quot;font-size: 12pt; line-height: 115%;&quot;&gt;&lt;span style=&quot;font-family: Calibri;&quot;&gt;Facebook&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: 12pt; line-height: 115%;&quot;&gt;&lt;a href=&quot;https://www.facebook.com/pages/Andrew-Avetikovs-Health-Fund/487664297941785&quot;&gt;&lt;span style=&quot;color: blue; font-family: Calibri;&quot;&gt;https://www.facebook.com/pages/Andrew-Avetikovs-Health-Fund/487664297941785&lt;/span&gt;&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/5864857356049547287/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/02/help-support-andrews-health-fund.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/5864857356049547287'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/5864857356049547287'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2013/02/help-support-andrews-health-fund.html' title='Help Support Andrew&#39;s Health Fund'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhF1TbDXrs5AkrJWY99K-ED5JhFAC25k3qdwqqGSJsGhe-kVOqec3uMtQfegV-h2S4gfZ67wl2digJ8sAGQhSFiZuAJkv-mKgKiwbNsSjryusS1lPah4ZzsIAoFEDjMrE4oM0ymGxF50Ffo/s72-c/Andrew+Avetikov.jpg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-1643248981394328260</id><published>2012-05-20T09:59:00.001-07:00</published><updated>2012-05-20T09:59:48.442-07:00</updated><title type='text'>Pennies in Action 2012</title><content type='html'>&lt;iframe allowfullscreen=&quot;&quot; frameborder=&quot;0&quot; height=&quot;344&quot; src=&quot;http://www.youtube.com/embed/zcHDjZCmsvc?fs=1&quot; width=&quot;459&quot;&gt;&lt;/iframe&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/1643248981394328260/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2012/05/pennies-in-action-2012.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/1643248981394328260'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/1643248981394328260'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2012/05/pennies-in-action-2012.html' title='Pennies in Action 2012'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://img.youtube.com/vi/zcHDjZCmsvc/default.jpg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-6309218960037629422</id><published>2010-07-26T06:33:00.000-07:00</published><updated>2010-07-26T06:33:05.978-07:00</updated><title type='text'>The Search For The Cure</title><content type='html'>&lt;object width=&quot;425&quot; height=&quot;344&quot;&gt;&lt;param name=&quot;movie&quot; value=&quot;http://www.youtube.com/v/2-z3RVwReEg&amp;amp;hl=en_US&amp;amp;fs=1&quot;&gt;&lt;param name=&quot;allowFullScreen&quot; value=&quot;true&quot;&gt;&lt;param name=&quot;allowscriptaccess&quot; value=&quot;always&quot;&gt;&lt;embed src=&quot;http://www.youtube.com/v/2-z3RVwReEg&amp;amp;hl=en_US&amp;amp;fs=1&quot; width=&quot;425&quot; height=&quot;344&quot; allowscriptaccess=&quot;never&quot; allowfullscreen=&quot;true&quot; wmode=&quot;transparent&quot; type=&quot;application/x-shockwave-flash&quot;&gt;&lt;/embed&gt;&lt;/object&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/6309218960037629422/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/07/search-for-cure.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/6309218960037629422'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/6309218960037629422'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/07/search-for-cure.html' title='The Search For The Cure'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-6422837636597585283</id><published>2010-07-21T05:32:00.000-07:00</published><updated>2010-07-21T05:32:12.632-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Avastin"/><category scheme="http://www.blogger.com/atom/ns#" term="bevacizumab"/><category scheme="http://www.blogger.com/atom/ns#" term="Breast cancer"/><category scheme="http://www.blogger.com/atom/ns#" term="FDA"/><title type='text'>Avastin: Advisory panel recommends FDA to remove advanced breast cancer indication</title><content type='html'>&lt;span&gt;&lt;/span&gt;&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=141969961X&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;/span&gt;GAITHERSBURG, Md. – In a vote of 12 to 1 a recommendation has been issued by the Oncologic Drugs Advisory Committee advisory panel that the FDA remove the advanced breast cancer indication from Avastin (bevacizumab), after two large clinical trials failed to demonstrate a clinically significant benefit of the drug, which is associated with serious side effects. When used in combination with standard chemotherapy, Avastin did not extend progression-free survival (PFS) long enough to be clinically significant in HER2-negative, metastatic breast cancer.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
In 2008, the FDA granted special, fast-track approval to Genentech, manufacturer of Avastin, to begin marketing the drug for patients with metastatic breast cancer in combination with the chemotherapy agent paclitaxel. This &quot;accelerated&quot; approval was based on positive early findings from a large Genentech-sponsored clinical trial that found Avastin added 5.5 months PFS vs. paclitaxel alone. However, the data from two new clinical trials (AVADO, RIBBON-1) of almost 2,000 breast cancer patients that Genentech submitted to move from accelerated approval to standard approval failed to demonstrate the PFS to the extent seen in the earlier study.* The PFS in the two trials ranged from a little less than a month, to just under three months. The results failed to demonstrate that the benefits of using Avastin outweigh the potential risks, which include a small risk of death, bleeding, febrile neutropenia and hypertension. &lt;br /&gt;
&lt;br /&gt;
&lt;div style=&quot;text-align: center;&quot;&gt;&lt;em&gt;&quot;Survival trumps everything, and we haven&#39;t shown a survival benefit here&quot;&lt;/em&gt;&lt;/div&gt;&lt;div style=&quot;text-align: center;&quot;&gt;&lt;em&gt;- Ronald Richardson, MD, a medical oncologist at the Mayo Clinic&lt;/em&gt;&lt;/div&gt;&lt;br /&gt;
Genentech argued that even small gains in progression-free survival are clinically meaningful and that additional weeks where tumors don&#39;t worsen translate to improved quality of life.&lt;br /&gt;
&lt;br /&gt;
The FDA usually follows the advice of its advisory committee, and if they do this time, Avastin would still be approved to treat lung, kidney, and colon cancer. Avastin is also used treat recurrent glioblastoma under accelerated approval. The FDA will make a decision by September 17, 2010.&lt;br /&gt;
&lt;br /&gt;
&lt;div style=&quot;text-align: left;&quot;&gt;&lt;span style=&quot;font-size: x-small;&quot;&gt;&lt;span style=&quot;background-color: white; color: black;&quot;&gt;*For details of the studies see &lt;em&gt;Avastin did not improve progression-free survival in patients with breast cancer&lt;/em&gt;. Available at &lt;/span&gt;&lt;a href=&quot;http://medwritehealthcarecommunications.blogspot.com/2010/07/avastin-did-not-improve-progression.html&quot;&gt;&lt;span style=&quot;background-color: white; color: black;&quot;&gt;http://medwritehealthcarecommunications.blogspot.com/2010/07/avastin-did-not-improve-progression.html&lt;/span&gt;&lt;/a&gt;&lt;span style=&quot;background-color: white; color: black;&quot;&gt;. Posted July 19, 2010.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;br /&gt;
&lt;strong&gt;Source&lt;/strong&gt;&lt;br /&gt;
FDA Panel Nixes Bevacizumab for Breast Cancer. By Emily P. Walker, Washington Correspondent, MedPage Today Published: July 20, 2010. Available at http://www.medpagetoday.com/HematologyOncology/BreastCancer/21276?utm_content=Group_&amp;amp;utm_medium=email&amp;amp;impressionId=&amp;amp;utm_campaign=DailyHeadlines&amp;amp;utm_source=mSpoke&amp;amp;userid= Accessed July 21, 2010.&lt;br /&gt;
&lt;br /&gt;
&lt;span&gt;&lt;/span&gt;&lt;br /&gt;
&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=0471610917&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;span&gt;&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=1420073540&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;span&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=0758202911&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/6422837636597585283/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/07/avastin-advisory-panel-recommends-fda.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/6422837636597585283'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/6422837636597585283'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/07/avastin-advisory-panel-recommends-fda.html' title='Avastin: Advisory panel recommends FDA to remove advanced breast cancer indication'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-3575940442142140261</id><published>2010-07-19T06:21:00.000-07:00</published><updated>2010-07-19T06:21:37.729-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Avastin"/><category scheme="http://www.blogger.com/atom/ns#" term="Breast cancer"/><category scheme="http://www.blogger.com/atom/ns#" term="chemotherapy"/><title type='text'>Avastin did not improve progression-free survival in patients with breast cancer</title><content type='html'>Two new studies demonstrated that Avastin (bevacizumab), in combination with chemotherapy did not extend progression free survival (PFS) in patients with advanced breast cancer to the same levels observed in a previous trial used to garner approval of the drug in this indication in 2008. The FDA approved Avastin for treatment of breast cancer was based on results from the E2100 clinical trial, which demonstrated that Avastin in combination with paclitaxel slowed the spread of breast cancer and extended PFS by 5.5 months vs. paclitaxel alone.[1-2] &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Data from two post-approval trials told a different story. A first, the AVADO clinical trial involving 736 patients with locally recurrent or metastatic HER2-negative breast cancer who had not previously received chemotherapy for their disease showed that a high dose of Avastin used in combination with docetaxel extended PFS by 0.9 months vs. docetaxel alone. Patients receiving a lower dose of Avastin had PFS extended by 0.8 months.[&lt;span style=&quot;font-size: x-small;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;3]&lt;/span&gt; &lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
A second post-approval trial, RIBBON-1 study involving 1237 women with locally recurrent or metastatic HER-2 negative breast cancer who had not received prior treatment for the disease demonstrated that Avastin in combination with taxane or anthracycline-based chemotherapies extended PFS by 1.2 months vs. chemotherapy alone. Patients receiving Avastin in combination with Xeloda (capecitabine) lived 2.9 months longer than patients receiving chemotherapy alone.[4] &lt;br /&gt;
&lt;br /&gt;
Currently, Avastin is indicated for the use in: (1) first-line treatment of a subgroup of women with metastatic breast cancer known as HER2-negative breast cancer, in combination with the chemotherapy drug docetaxel; and (2) first-line treatment of HER2-negative metastatic breast cancer in combination with one of two classes of chemotherapy drugs, known as taxanes and anthracyclines, or with the chemotherapy drug, capecitabine. FDA approval is pending of additional indication for the treatment, in combination with the chemotherapy drug paclitaxel, of patients who have not received chemotherapy for their locally recurrent or metastatic HER2 negative breast cancer. The FDA may ultimately decide to withdraw its approval for Avastin based on results from the post-approval trials.&lt;br /&gt;
&lt;br /&gt;
&lt;strong&gt;References:&lt;/strong&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: x-small;&quot;&gt;1. FDA staff release review of Roche&#39;s Avastin in breast cancer. First Word. Light Edition. July 16, 2010. Available at http://www.firstwordplus.com/Fws.do?articleid=F731F4EE99584F0FB11A106C99246301 Accessed July 19, 2010.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: x-small;&quot;&gt;2. July 20, 2010: Oncologic Drugs Advisory Committee Meeting Announcement. FDA U.S. Food and Drug Administration. Available at http://www.fda.gov/AdvisoryCommittees/Calendar/ucm213724.htm Accessed July 19, 2010.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: x-small;&quot;&gt;3. Miles D, Chan A, G. Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26: 2008 (May 20 suppl; abstr LBA1011). Available at http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;amp;vmview=abst_detail_view&amp;amp;confID=55&amp;amp;abstractID=34482 Accessed July 19, 2010.&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-size: x-small;&quot;&gt;4. Robert NJ, Dieras V, J. Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27:15s, 2009 (suppl; abstr 1005). Available at http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;amp;vmview=abst_detail_view&amp;amp;confID=65&amp;amp;abstractID=34532 Accessed July 19, 2010.&lt;/span&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=0801886856&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/3575940442142140261/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/07/avastin-did-not-improve-progression.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/3575940442142140261'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/3575940442142140261'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/07/avastin-did-not-improve-progression.html' title='Avastin did not improve progression-free survival in patients with breast cancer'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-3888164844531437405</id><published>2010-06-14T06:15:00.000-07:00</published><updated>2010-06-14T06:40:14.498-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="angiotensin-receptor blocker"/><category scheme="http://www.blogger.com/atom/ns#" term="Blood pressure drugs"/><category scheme="http://www.blogger.com/atom/ns#" term="cancer"/><title type='text'>Blood pressure drugs, angiotensin-receptor blockers, and risk of cancer: meta-analysis of randomized controlled trials</title><content type='html'>&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=B001MS7IPO&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;A recent study by Sipahi et al. published in The Lancet Oncology suggests that angiotensin-receptor blockers (ARBs) may be associated with a &quot;modestly&quot; increased risk of cancer. However, conclusions about the exact risk of cancer associated with each particular drug were not possible to draw due to study limitations.&lt;br /&gt;
&lt;br /&gt;
ARBs are a widely used drug class approved for treatment of hypertension, heart failure, diabetic nephropathy, and, recently, for cardiovascular risk reduction. Experimental studies implicate the renin-angiotensin system, particularly angiotensin II type-1 and type-2 receptors, in the regulation of cell proliferation, angiogenesis, and tumour progression. &lt;br /&gt;
&lt;br /&gt;
&lt;div&gt;This study assessed whether ARBs affect cancer occurrence with a meta-analysis of randomized controlled trials of these drugs by searching Medline, Scopus (including Embase), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and the US Food and Drug Administration website for studies published before November, 2009, that included any of the seven currently available ARBs.* Randomized controlled trials with an ARB given in at least one group, with a follow-up of at least 1 year, and that enrolled at least 100 patients were included. The following information was available:&lt;/div&gt;&lt;ul&gt;&lt;li&gt;New-cancer data for 61, 590 patients from five trials&lt;/li&gt;
&lt;li&gt;Data on common types of solid organ cancers for 68, 402 patients from five trials&lt;/li&gt;
&lt;li&gt;Data on cancer deaths for 93, 515 patients from eight trials.&lt;/li&gt;
&lt;/ul&gt;Telmisartan was the study drug in 30, 014 (85.7%) patients who received ARBs as part of the trials with new cancer data. Patients randomly assigned to receive ARBs had a significantly increased risk of new cancer occurrence compared with patients in control groups (7.2% vs 6.0%, risk ratio [RR] 1.08, 95% CI 1.01—1.15; p=0.016). When analysis was limited to trials where cancer was a prespecified endpoint, the RR was 1.11 (95% CI 1.04—1.18, p=0.001). Among specific solid organ cancers examined, only new lung cancer occurrence was significantly higher in patients randomly assigned to receive ARBs than in those assigned to receive control (0.9% vs 0.7%, RR 1.25, 1.05—1.49; p=0.01). No statistically significant difference in cancer deaths was observed (1.8% vs 1.6%, RR 1.07, 0.97—1.18; p=0.183).&lt;br /&gt;
&lt;br /&gt;
&lt;div&gt;This meta-analysis of randomized controlled trials suggested that ARBs were associated with a modestly increased risk of new cancer diagnosis. The researchers concluded that due to the limited data, it was not possible to draw conclusions about the exact risk of cancer associated with each particular drug, and these findings warranted further investigation.&lt;/div&gt;&lt;br /&gt;
*Drugs in this class include:&lt;br /&gt;
&lt;ul&gt;&lt;li&gt;Atacand (candesartan) (AstraZeneca)&lt;/li&gt;
&lt;li&gt;Avapro (irbesartan) (sanofi-aventis and Bristol Myers Squibb)&lt;/li&gt;
&lt;li&gt;Benicar (omesartan) (Daiichi Sankyo)&amp;nbsp;&lt;/li&gt;
&lt;li&gt;Cozaar (losartan) (Merck &amp;amp; Co.)&lt;/li&gt;
&lt;li&gt;Diovan (valsartan) (Novartis)&lt;/li&gt;
&lt;li&gt;Mycardis (telmisartan) (Boehringer Ingelheim and Astellas)&lt;/li&gt;
&lt;li&gt;Teveten (eprosartan) (Solvay) &lt;br /&gt;
&lt;strong&gt;&lt;/strong&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;strong&gt;Reference&lt;/strong&gt;&lt;br /&gt;
Sipahi I, Debanne SM, Rowland DY, et al. Blood pressure drugs, angiotensin-receptor blockers and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncol, Early Online Publication, 14 June 2010, doi:10.1016/S1470-2045(10)70106-6 .&lt;br /&gt;
&lt;br /&gt;
&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=0470275405&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/3888164844531437405/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/06/blood-pressure-drugs-angiotensin.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/3888164844531437405'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/3888164844531437405'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/06/blood-pressure-drugs-angiotensin.html' title='Blood pressure drugs, angiotensin-receptor blockers, and risk of cancer: meta-analysis of randomized controlled trials'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-8890344337763697136</id><published>2010-05-28T10:22:00.000-07:00</published><updated>2010-05-28T10:28:32.072-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="apoptosis"/><category scheme="http://www.blogger.com/atom/ns#" term="cancer"/><category scheme="http://www.blogger.com/atom/ns#" term="G2 cell cycle phase"/><category scheme="http://www.blogger.com/atom/ns#" term="malignant"/><category scheme="http://www.blogger.com/atom/ns#" term="reccurence"/><category scheme="http://www.blogger.com/atom/ns#" term="stem cells"/><title type='text'>Stem-cell-like properties of normal and malignant epithelial cells contribute to cell-death resistance</title><content type='html'>&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=0521896282&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;It is not well understood why carcinomas reemerge after chemotherapy and/or radiation treatments. Cancer recurrence and treatment failure seems to be associated with stem-cell-like properties and resistance to apoptosis (programmed cell death) in a subset of cells that have been previously isolated from human epithelial cancers.&lt;br /&gt;
One study investigated the mechanisms of apoptosis resistance of cells with stem-cell-like properties in both normal and malignant human epithelia, and whether altered cell cycle regulation played a role.&lt;br /&gt;
&lt;br /&gt;
To address these questions, the following methodology was employed:&lt;br /&gt;
&lt;ul&gt;&lt;li&gt;Cells were isolated from fresh human head and neck carcinomas (n = 11), cell lines derived from head and neck, prostate and breast human carcinomas (n = 7), and from normal human oral mucosa (n = 5)&lt;/li&gt;
&lt;li&gt;All cells were exposed to various apoptosis-inducing stimuli (UV, tumour necrosis factor, cisplatin, etoposide, and neocarzinostatin)&lt;/li&gt;
&lt;li&gt;The subset of cells with stem-cell-like properties were identified by flow cytometry for CD44 and epithelial-specific antigen (ESA) expression, colony morphology, tumour sphere formation and rapid adherence assays&lt;/li&gt;
&lt;li&gt;Apoptosis, cell cycle and expression of various cell cycle checkpoint proteins were assessed by Western Blot and quantitative PCR (qPCR)&lt;/li&gt;
&lt;li&gt;&amp;nbsp;Debromohymenialdisine (DBH) and small interfering RNA (siRNA) were used to investigate the role of G2-checkpoint regulators Chk1 and Chk2&lt;/li&gt;
&lt;/ul&gt;&amp;nbsp;The study demonstrated the following:&lt;br /&gt;
&lt;ul&gt;&lt;li&gt;&amp;nbsp;A subset of CD44high cells were found in both cancer biopsies and carcinoma cell lines that showed increased clonogenicity, a significantly lower rate of apoptosis, and a significantly higher proportion of cells in the G2-phase of the cell cycle. An inverse correlation between the Percentage of cells in G2-phase and the rate of apoptosis revealed an inverse correlation. &lt;/li&gt;
&lt;li&gt;It appeared that CD44high carcinoma cells spent longer time in G2, even in untreated controls as shown by pulse-chase with iododeoxyuridine (IdU). These cells expressed higher levels of G2 checkpoint proteins, and their release from G2 with BDH or Chk1 siRNA increased their rate of apoptosis. &lt;/li&gt;
&lt;li&gt;Interestingly, low passage cultures of normal keratinocytes were found to contain a subset of CD44high cells which also showed increased clonogenicity, and a similar pattern of G2-block associated with apoptotic resistance.&lt;/li&gt;
&lt;/ul&gt;&lt;br /&gt;
&lt;div&gt;&lt;strong&gt;&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=0470122013&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;/span&gt;Conclusions&lt;/strong&gt;&lt;/div&gt;The results of this study suggested that not only malignant, but also normal human epithelial cells with stem-cell-like properties have extended G2 cell cycle phase which is associated with greater resistance to apoptosis, and that this property is not a consequence of neoplastic (cancerous) transformation (i.e. not unique to cancer cells). This knowledge provides an opportunity for novel therapeutic approaches targeting G2 checkpoint proteins to release these cells from the G2-block and make them more prone to apoptosis.&lt;br /&gt;
&lt;br /&gt;
&lt;div&gt;&lt;/div&gt;&lt;strong&gt;Abbreviations&lt;/strong&gt;&lt;br /&gt;
PCR = polymerase chain reaction; RNA = ribonucleic acid&lt;br /&gt;
&lt;br /&gt;
&lt;div&gt;&lt;strong&gt;Reference&lt;/strong&gt;&lt;/div&gt;Harper LJ, Costea DE, Gammon L, &lt;em&gt;et al&lt;/em&gt;. Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer 2010, 10:166doi:10.1186/1471-2407-10-166.&lt;br /&gt;
&lt;br /&gt;
&lt;strong&gt;Free full-text article available at:&lt;/strong&gt; http://www.biomedcentral.com/1471-2407/10/166&lt;br /&gt;
&lt;br /&gt;
&lt;div&gt;&lt;/div&gt;&lt;br /&gt;
&lt;div&gt;&lt;/div&gt;&lt;br /&gt;
&lt;div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/8890344337763697136/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/stem-cell-like-properties-of-normal-and.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8890344337763697136'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8890344337763697136'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/stem-cell-like-properties-of-normal-and.html' title='Stem-cell-like properties of normal and malignant epithelial cells contribute to cell-death resistance'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-8415019383577225624</id><published>2010-05-24T14:49:00.000-07:00</published><updated>2010-05-24T14:55:45.032-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="exercise"/><category scheme="http://www.blogger.com/atom/ns#" term="fibromyalgia"/><category scheme="http://www.blogger.com/atom/ns#" term="physical activity"/><title type='text'>Exercise and its effects on perceived symptoms and physical function in adults with fibromyalgia: results from a randomized trial</title><content type='html'>&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=B000WLLWDQ&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;Adults with fibromyalgia (FM) have been shown to benefit from exercise and its therapeutic effects on their condition. However, FM symptoms often limit the ability to exercise and create obstacles that discourage an active lifestyle and physical activity. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
One study evaluated the effects of accumulating at least 30 minutes of self-selected lifestyle physical activity (LPA) on perceived physical function, pain, fatigue, body mass index, depression, tenderness, and the six-minute walk test in adults with FM.&lt;br /&gt;
&lt;br /&gt;
Eighty-four minimally active adults with FM were randomized to either LPA or a FM education control (FME) group. Participants in the LPA group worked toward accumulating 30 minutes of self-selected moderate-intensity LPA, 5–7 days per week, while the FME participants received only information and support.&lt;br /&gt;
&lt;br /&gt;
Of the 84 participants, 73 (87%) completed the 12-week trial. The LPA group increased their average daily steps by 54%. As well, the LPA group reported significantly less perceived functional deficits (P = 0.032) and less pain (P = 0.006) compared to the FME group. No differences between the groups were seen on the six-minute walk test (P = 0.067), fatigue, depression, body mass index, or tenderness.&lt;br /&gt;
&lt;br /&gt;
This study demonstrated that accumulating as little as 30 minutes of LPA throughout the day can produce clinically relevant changes in how previously minimally active adults with FM perceive physical function and pain.&lt;br /&gt;
&lt;br /&gt;
&lt;strong&gt;Reference&lt;/strong&gt;&lt;br /&gt;
&lt;br /&gt;
Fontaine KR, Conn L, and Clauw DJ. Effects of lifestyle physical activity on perceived symptoms and physical function in adults with fibromyalgia: results of a randomized trial. Arthr ResTher 2010; 12:R55doi:10.1186/ar2967&lt;br /&gt;
&lt;br /&gt;
&lt;span style=&quot;color: black;&quot;&gt;&lt;strong&gt;Article URL&lt;/strong&gt;: &lt;/span&gt;&lt;a href=&quot;http://arthritis-research.com/content/12/2/R55&quot;&gt;&lt;span style=&quot;color: black;&quot;&gt;http://arthritis-research.com/content/12/2/R55&lt;/span&gt;&lt;/a&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=B000WTVYYA&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=188288356X&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=158054326X&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/8415019383577225624/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/exercise-and-its-effects-on-perceived.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8415019383577225624'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8415019383577225624'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/exercise-and-its-effects-on-perceived.html' title='Exercise and its effects on perceived symptoms and physical function in adults with fibromyalgia: results from a randomized trial'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-6137776529498316964</id><published>2010-05-22T16:11:00.000-07:00</published><updated>2010-05-22T16:11:59.293-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="mood"/><category scheme="http://www.blogger.com/atom/ns#" term="phychological health"/><category scheme="http://www.blogger.com/atom/ns#" term="Tai Chi"/><category scheme="http://www.blogger.com/atom/ns#" term="well-being"/><title type='text'>Effect of Tai Chi on psychological well-being: systematic review and meta-analysis</title><content type='html'>&lt;span&gt;&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=B002QRAXRK&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;
Psychological health seems to benefit from physical activity and exercise, but the effects of Tai Chi on psychological well-being have rarely been examined quantitatively. In this study, a systematic review of the effects of Tai Chi on stress, anxiety, depression and mood disturbance in eastern and western populations was performed. &lt;br /&gt;
&lt;br /&gt;
Eleven databases (8 English and 3 Chinese) were searched through March 2009. The studies examined included: randomized controlled trials, non-randomized controlled studies and observational studies reporting at least 1 psychological health outcome. Data extraction and verification was analyzed by 3 reviewers. Meta-analysis was performed on randomized trials in each subcategory of health outcomes using a random-effects model, and the quality of each study was assessed. &lt;br /&gt;
&lt;br /&gt;
&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=B00153142E&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;/span&gt;Forty studies were identified with a total of 3817 subjects. Approximately 29 psychological measurements were assessed. Twenty-three of 33 randomized and non-randomized trials demonstrated that a duration of 1 hour to 1 year of regular Tai Chi significantly increased psychological well-being including reduction of stress (effect size [ES], 0.66; 95% confidence interval [CI], 0.23 to 1.09), anxiety (ES, 0.66; 95% CI, 0.29 to 1.03), and depression (ES, 0.56; 95% CI, 0.31 to 0.80), and enhanced mood and emotion (ES, 0.45; 95% CI, 0.20 to 0.69) in community-dwelling healthy participants as well as in patients with chronic conditions. Seven observational studies with relatively large sample sizes confirmed the beneficial link between Tai Chi practice and psychological health. &lt;br /&gt;
&lt;br /&gt;
Overall, Tai Chi appears to be associated with improvements in psychological well-being including reduced stress, anxiety, depression and mood disturbance, and increased self-esteem. &lt;br /&gt;
&lt;br /&gt;
Variation in designs, comparisons, heterogeneous outcomes and inadequate controls of the studies reviewed were the limiting factors towards drawing definitive conclusions. Well-controlled, high quality randomized trials of longer durations are needed to confirm the findings of this review in order to make more informed clinical decisions. &lt;br /&gt;
&lt;br /&gt;
&lt;strong&gt;Reference&lt;/strong&gt;&lt;br /&gt;
Wang C, Bannuru R, Ramel J, et al. Tai Chi on psychological well-being: systematic review and meta-analysis. BMC Complem Alter Med 2010, 10:23doi:10.1186/1472-6882-10-23&lt;br /&gt;
&lt;br /&gt;
&lt;strong&gt;Article URL&lt;/strong&gt; &lt;a href=&quot;http://www.biomedcentral.com/1472-6882/10/23&quot;&gt;http://www.biomedcentral.com/1472-6882/10/23&lt;/a&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=B001KRCDRK&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=B001N4K6M4&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;span&gt;&lt;iframe align=&quot;left&quot; frameborder=&quot;0&quot; marginheight=&quot;0&quot; marginwidth=&quot;0&quot; scrolling=&quot;no&quot; src=&quot;http://rcm.amazon.com/e/cm?t=medwrite-20&amp;amp;o=1&amp;amp;p=8&amp;amp;l=bpl&amp;amp;asins=B002IVLWDI&amp;amp;fc1=000000&amp;amp;IS2=1&amp;amp;lt1=_blank&amp;amp;m=amazon&amp;amp;lc1=0000FF&amp;amp;bc1=000000&amp;amp;bg1=FFFFFF&amp;amp;f=ifr&quot; style=&quot;align: left; height: 245px; padding-right: 10px; padding-top: 5px; width: 131px;&quot;&gt;&lt;/iframe&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/6137776529498316964/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/effect-of-tai-chi-on-psychological-well.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/6137776529498316964'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/6137776529498316964'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/effect-of-tai-chi-on-psychological-well.html' title='Effect of Tai Chi on psychological well-being: systematic review and meta-analysis'/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-8685345301590677571</id><published>2010-05-19T11:10:00.000-07:00</published><updated>2010-05-19T11:15:19.775-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="caffeine"/><category scheme="http://www.blogger.com/atom/ns#" term="resistance training"/><category scheme="http://www.blogger.com/atom/ns#" term="strength enhancement"/><title type='text'></title><content type='html'>&lt;strong&gt;&lt;span style=&quot;color:#990000;&quot;&gt;Caffeine and upper body strength enhancement in resistance-trained women&lt;/span&gt;&lt;/strong&gt;&lt;br /&gt;&lt;span style=&quot;font-family:verdana;&quot;&gt;Research has shown that low-to-moderate dosages of caffeine supplementation are ergogenic for sustained endurance efforts and high-intensity exercise. The effects of caffeine supplementation on strength-power performance are conflicting since some studies have indicated a benefit while others suggested no change in performance. While the majority of research that has examined the effects of caffeine supplementation on strength-power performance has been done in both trained and untrained men, no equivalent studies have been performed in women. The purpose of this study was to determine the acute effects of caffeine supplementation on strength and muscular endurance in resistance-trained women.&lt;br /&gt;&lt;br /&gt;Fifteen women were randomized to consume caffeine (6 mg/kg) or placebo (PL) seven days apart. Sixty minutes after caffeine supplementation, participants performed a one-repetition maximum (1RM) barbell bench press test and repetitions to failure (RF) at 60% of 1RM. Heart rate (HR) and blood pressure (BP) were assessed at rest, 60 minutes post-consumption, and immediately following completion of repetitions to failure.&lt;br /&gt;&lt;br /&gt;It was demonstrated that significantly greater bench press maximum was achieved with caffeine (p≤0.05) (52.9 ± 11.1 kg vs. 52.1 ± 11.7 kg) with no significant differences between conditions in 60% 1RM repetitions (p=0.81).* Further, post-exercise systolic blood pressure was significantly greater with caffeine vs. placebo (p&lt;0.05)&gt;&lt;br /&gt;&lt;span style=&quot;font-family:verdana;&quot;&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-family:verdana;&quot;&gt;*Repeated measures ANOVA &lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-family:verdana;&quot;&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-family:verdana;&quot;&gt;&lt;strong&gt;Reference&lt;/strong&gt;&lt;br /&gt;Goldstein ER, Jacobs PL, Michael Whitehurst M, et al. Caffeine enhances upper body strength in resistance-trained women. J Int Soc Sports Nutr 2010, 7:18doi:10.1186/1550-2783-7-18&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;Article URL&lt;/strong&gt; http://www.jissn.com/content/7/1/18 &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;span style=&quot;font-family:verdana;&quot;&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/8685345301590677571/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/caffeine-and-upper-body-strength.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8685345301590677571'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/8685345301590677571'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/caffeine-and-upper-body-strength.html' title=''/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-2727338753464629487</id><published>2010-05-12T07:56:00.000-07:00</published><updated>2010-05-12T07:58:21.896-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="bone"/><category scheme="http://www.blogger.com/atom/ns#" term="bone density"/><category scheme="http://www.blogger.com/atom/ns#" term="bone mineral"/><category scheme="http://www.blogger.com/atom/ns#" term="lean muscle"/><category scheme="http://www.blogger.com/atom/ns#" term="muscle"/><category scheme="http://www.blogger.com/atom/ns#" term="muscle mass"/><title type='text'></title><content type='html'>&lt;strong&gt;&lt;span style=&quot;color:#660000;&quot;&gt;Greater lean tissue and skeletal muscle mass in children contributes to higher bone mineral content&lt;/span&gt;&lt;/strong&gt;&lt;br /&gt;&lt;br /&gt;In a recent study, the relationship of skeletal muscle mass with bone mineral content was compared in an ethnically diverse group of 6–18 year old boys and girls.&lt;br /&gt;&lt;br /&gt;Body mass, height, and Tanner stage were assessed in 175 healthy children (103 boys, 72 girls). Dual-energy X-ray absorptiometry (DXA) was used to assess whole body bone mineral content, non-bone lean body mass, skeletal muscle mass, and fat mass. To estimate muscle mass, an equation using appendicular lean soft tissue measured by DXA, weight and height was used. Whole body multi-slice magnetic resonance imaging (MRI) was used to estimate skeletal muscle mass and adipose tissue.&lt;br /&gt;&lt;br /&gt;This study, which was among the first to describe and compare the relationship of skeletal muscle to bone using both MRI and DXA estimates, demonstrated that greater skeletal muscle mass was associated with greater bone mineral content (p&lt;0.001). The skeletal muscle mass assessed by MRI provided a better model for the relationship of skeletal muscle to bone compared with assessment by DXA for predicting bone mineral content. The proportion of skeletal muscle mass in non-bone lean body mass was significantly associated with greater bone mineral content adjusted for total non-bone lean body mass. Children of Hispanic origin had greater bone mineral content compared to other race and ethnic groups after adjusting for sex, age, adipose tissue, skeletal muscle mass, and height.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;* To determine whether skeletal muscle mass assessed by DXA or by MRI were better predictors of bone mineral content compared with non-bone lean body mass after adjusting for sex, age, race or ethnicity, and Tanner stage, linear regression model as determined by R2 statistic was used.&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;Reference &lt;/strong&gt;&lt;br /&gt;Dorsey KB, John C Thornton JC, Heymsfield SB, Gallagher D. Greater lean tissue and skeletal muscle mass are associated with higher bone mineral content in children. Nutrition &amp;amp; Metabolism 2010, 7:41 doi:10.1186/1743-7075-7-41&lt;br /&gt;&lt;br /&gt;Article URL http://www.nutritionandmetabolism.com/content/7/1/41</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/2727338753464629487/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/greater-lean-tissue-and-skeletal-muscle_8816.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/2727338753464629487'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/2727338753464629487'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/greater-lean-tissue-and-skeletal-muscle_8816.html' title=''/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-4471322497624791053</id><published>2010-05-11T19:33:00.000-07:00</published><updated>2010-05-11T19:38:42.726-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="C. difficile"/><category scheme="http://www.blogger.com/atom/ns#" term="PPI"/><category scheme="http://www.blogger.com/atom/ns#" term="Proton pump inhibitors"/><title type='text'></title><content type='html'>&lt;div align=&quot;left&quot;&gt;&lt;span style=&quot;font-family:verdana;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color:#990000;&quot;&gt;Possible link between proton pump inhibitors and increase of bone fractures and risk of bacterial infection&lt;/span&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-family:verdana;&quot;&gt;&lt;span style=&quot;color:#000000;&quot;&gt;Each year, 113.4 million prescriptions for proton pump inhibitors (PPIs) are filled in the United States, making this class of drugs, the third highest seller at $13.9 billion in sales. PPIs have demonstrated efficacy for treatment of erosive and ulcerative esophagitis, Barrett esophagus, Zollinger-Ellison syndrome, and gastroesophageal reflux disease (GERD), as well as for short-term treatment of ulcer disease, as part of a combination regimen for Helicobacter pylori eradication and for prevention of ulcers due to nonsteroidal anti-inflammatory drugs. These indications, however, do not account for more than a hundred million prescriptions, which is supported by evidence that PPIs have been shown to be overprescribed, where between 53% and 69% of PPI prescriptions are prescribed off-label.&lt;br /&gt;&lt;br /&gt;Recent research published in the Archives of Internal Medicine (&lt;em&gt;Arch Intern Med&lt;/em&gt;. 2010;170(9):747-748), demonstrated (PPIs) increase the risk of bone fractures in older woman and are also associated with an increased risk of &lt;em&gt;Clostridium difficile&lt;/em&gt; (&lt;em&gt;C. difficile&lt;/em&gt;) infection.&lt;br /&gt;&lt;br /&gt;In one study, data was analyzed on 161, 806 women aged 50 to 79 without a history of hip fracture enrolled in the Women&#39;s Health Initiative. After eight years, 21, 247 bone fractures were observed. Women who were on PPIs had 47% increased risk of spinal fracture, 26% increased risk for forearm or wrist fracture, and 25% increased risk of total fractures, compared to women who did not take PPIs. However, the use of PPIs was not associated with an increased risk of hip fracture and only a minimal effect on bone mineral density was observed over three years.&lt;br /&gt;&lt;br /&gt;Another study examined the records of 101,796 patients discharged from a Massachusetts hospital between 2004 and 2008. The study demonstrated that patients treated with PPIs had 74% increase of &lt;em&gt;C. difficile&lt;/em&gt; infections compared with those not taking the drugs. In addition, a different study on 1,200 patients treated for the bacterial infection demonstrated a 42% increased risk of recurrent infection in patients taking PPIs compared to those not taking the drugs. According to researcher Michael Howell, it appears that the acidity of the stomach may confer immunity to &lt;em&gt;C. difficile&lt;/em&gt;, and suppressing the acidity with PPIs, increases the risk of &lt;em&gt;C. difficile&lt;/em&gt; infection.&lt;br /&gt;&lt;br /&gt;The results of these studies suggest that although PPIs do work, PPI-related adverse effects may outweigh the benefits for some patients and should be used with caution. Further research through prospective, controlled studies is necessary to establish a link between PPIs and fractures, and PPIs and &lt;em&gt;C. difficile&lt;/em&gt; infections.&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;Reference&lt;/strong&gt;&lt;br /&gt;Katz MH. LESS IS MORE: Failing the Acid Test. Benefits of Proton Pump Inhibitors May Not Justify the Risks for Many Users. Arch Intern Med. 2010;170(9):747-748.&lt;br /&gt;&lt;br /&gt;&lt;strong&gt;Related Articles&lt;/strong&gt;&lt;br /&gt;Grady D and Redberg RF. Less Is More: How Less Health Care Can Result in Better Health. Arch Intern Med. 2010;170(9):749-750.&lt;br /&gt;&lt;br /&gt;Gray SL, LaCroix AZ, Larson J, et al. Proton Pump Inhibitor Use, Hip Fracture, and Change in Bone Mineral Density in Postmenopausal Women: Results From the Women&#39;s Health Initiative. Arch Intern Med. 2010;170(9):765-771.&lt;br /&gt;&lt;br /&gt;Howell MD, Novack V, Grgurich P, et al. Iatrogenic Gastric Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection. Arch Intern Med. 2010;170(9):784-790.&lt;br /&gt;&lt;br /&gt;Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection. Arch Intern Med. 2010;170(9):772-778.&lt;br /&gt;&lt;br /&gt;Wang C-H, Ma M H-M, Chou H-C, Yen Z-S, et al. High-Dose vs Non–High-Dose Proton Pump Inhibitors After Endoscopic Treatment in Patients With Bleeding Peptic Ulcer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Arch Intern Med. 2010;170(9):751-758.&lt;br /&gt;&lt;br /&gt;Yachimski PS, Farrell EA, Hunt DP, Reid AE. Proton Pump Inhibitors for Prophylaxis of Nosocomial Upper Gastrointestinal Tract Bleeding: Effect of Standardized Guidelines on Prescribing Practice. Arch Intern Med. 2010;170(9):779-783.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/4471322497624791053/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/possible-link-between-proton-pump.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/4471322497624791053'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/4471322497624791053'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/05/possible-link-between-proton-pump.html' title=''/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-1404336851463042010.post-1740673141077867494</id><published>2010-04-28T11:39:00.000-07:00</published><updated>2010-04-28T11:40:38.445-07:00</updated><title type='text'></title><content type='html'>Welcome to MedWrite Healthcare Communications in Toronto, Ontario, Canada!&lt;br /&gt;&lt;br /&gt;Our Mission is to provide accurate, creative and timely healthcare, medical or pharmaceutical communication materials using evidence-based scientific and clinical information. &lt;br /&gt;&lt;br /&gt;We have expertise on a diversity of pharmaceutical brands spanning a wide range of therapeutic areas for both professional and consumer audiences.&lt;br /&gt;&lt;br /&gt;At MedWrite Healthcare Communication we specialize in....  &lt;br /&gt;- Healthcare Advertising &lt;br /&gt;- Continuing Medical Education (CME) &lt;br /&gt;- Web Content  &lt;br /&gt;- Scientific Publications   &lt;br /&gt;- Health &amp; Fitness&lt;br /&gt;- Nutrition&lt;br /&gt;&lt;br /&gt;MedWrite can help you create: &lt;br /&gt;&lt;br /&gt;1. Healthcare advertising promotional materials in compliance with the Pharmaceutical Advertising Advisory Board (PAAB) and Rx&amp;D codes, and the FDA regulations, for both professional and lay audiences   &lt;br /&gt;2. Continuing Medical Education (CME) materials for healthcare professionals &lt;br /&gt;3. Patient healthcare educational information  &lt;br /&gt;4. Scientific Conference and Advisory Board Meeting coverage and reports &lt;br /&gt;5. Consensus Statements and Clinical Treatment Guidelines  &lt;br /&gt;6. Needs Assessments &lt;br /&gt;7. Healthcare communication materials across a wide range of therapeutic areas and topics &lt;br /&gt;&lt;br /&gt;...and more...&lt;br /&gt;&lt;br /&gt;For more information please visit http://www.medwrite-canada.com</content><link rel='replies' type='application/atom+xml' href='http://medwritehealthcarecommunications.blogspot.com/feeds/1740673141077867494/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/04/welcome-to-medwrite-healthcare.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/1740673141077867494'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/1404336851463042010/posts/default/1740673141077867494'/><link rel='alternate' type='text/html' href='http://medwritehealthcarecommunications.blogspot.com/2010/04/welcome-to-medwrite-healthcare.html' title=''/><author><name>Anonymous</name><uri>http://www.blogger.com/profile/01499242503519392685</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry></feed>